Eyedeal Completes RMB 100 Million Series B Financing to Accelerate Product Commercialization

Recently, Xi’an Eyedeal Medical Technology Co., Ltd. announced the successful completion of its Series B financing round, raising hundreds of millions of RMB. The round was led by YuanBio Venture Capital, with follow-on investments from Sino-European Century and PAG. The funds will be used to accelerate the clinical development and commercialization of Eyedeal’s next-generation intraocular lens (IOL) made from innovative materials, as well as its existing product portfolio.

“In the post-pandemic era, especially amid tightened global capital and increasingly cautious investments, the successful completion of this financing round once again demonstrates strong investor confidence in Eyedeal’s innovation capabilities and its ophthalmic product portfolio,” said Founder Mr. Guangxu Guo.

In 2014, Mr. Guo partnered with Dr. Len Pinchuk, a member of the U.S. National Academy of Engineering, acquiring his material invention patents and officially established Xi’an Eyedeal in 2015. Since then, Eyedeal has assembled a world-class technical team led by top academicians and senior experts in materials science, optics, mechanics, and biomedical engineering from both China and abroad. The company has also established research platforms such as the Shaanxi Provincial Engineering Research Center and a postdoctoral innovation base, and has attracted and trained a number of PhD-level professionals, with R&D personnel making up more than 80% of its staff.

After nearly ten years of continuous innovation, Eyedeal has developed the world’s latest generation of intraocular lens using its proprietary cross-linked polyisobutylene (xPIB) medical polymer material. In November 2021, it launched a nationwide multi-center clinical trial—the first new-material IOL to enter clinical trials in the global ophthalmic field in nearly 30 years.

The xPIB IOL offers superior biocompatibility, material stability, and outstanding optical and mechanical properties. Its ultra-large optical zone and micro-incision implantation provide safer and longer-lasting clinical benefits for cataract patients.

Professor Gerd Auffarth, Director of the David J. Apple Laboratory—recognized as the global gold standard in ophthalmology—and professor at Heidelberg University in Germany, commented: xPIB IOL is an innovative material—no glistenings, no glare, smaller incisions, larger optics, and minimal inflammatory response. It is currently the most ideal intraocular lens.”

Thanks to the innovative achievements of its xPIB intraocular lens, Eyedeal was approved for a key project under China’s Ministry of Science and Technology “National Key R&D Program” and, in 2020, the product was included in the National Medical Products Administration’s (NMPA) Special Review Pathway for Innovative Medical Devices. The product’s Chinese clinical trial enrollment has been completed, while the European clinical trial was officially launched this month.

In October 2022, Eyedeal’s independently developed hydrophobic acrylic aspheric intraocular lens received market approval from the NMPA. Benchmarking industry-leading products, this lens can better meet the clinical needs.

In addition to intraocular lenses for cataract treatment, Eyedeal is also focused on high-end ophthalmic medical devices, actively developing solutions for a variety of eye diseases. The company is committed to becoming a globally influential industry leader that integrates raw material synthesis, product R&D, manufacturing, and commercialization.

Leimin Gu, Partner at YuanBio Venture Capital, said:“Ophthalmic medical devices have always been a focus for us. Under the leadership of Mr. Guo, Eyedeal has built a strong foundation and outstanding R&D capability, resulting in an innovative and diverse product pipeline. The company’s strengths in material innovation and polymer synthesis stand out. With a world-class team of scientists, Eyedeal has created a pragmatic, experienced, and highly efficient organization. We are very confident in its future growth.”

Yao Wei, Head of Sino-European Century, noted:“We are pleased to have the opportunity to invest in Eyedeal. The company has a strong team and leading capabilities in IOL innovation, polymer materials, and manufacturing processes. We look forward to seeing Eyedeal reach new heights in its development journey.”

PAG added:“We first invested in Eyedeal during its Series A round in 2020 because we believed in the team and its potential. Over the past two years, the company has overcome numerous challenges and achieved significant milestones in product development, manufacturing, and innovation. We are even more confident in its trajectory. With our continued support in this Series B round, we look forward to witnessing Eyedeal’s continued success.”